Longeveron (NASDAQ:LGVN) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Longeveron (NASDAQ:LGVN) in a research report sent to investors on Monday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Longeveron’s Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.20) EPS.

A number of other brokerages have also recently issued reports on LGVN. Roth Capital upgraded Longeveron to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm began coverage on Longeveron in a report on Friday, December 6th. They set a “buy” rating and a $10.00 price objective on the stock.

Longeveron Trading Up 5.3 %

Shares of LGVN opened at $1.40 on Monday. Longeveron has a 1 year low of $0.77 and a 1 year high of $6.40. The stock has a market cap of $20.77 million, a P/E ratio of -0.22 and a beta of 0.36. The stock’s 50-day moving average price is $1.64 and its two-hundred day moving average price is $1.89.

Hedge Funds Weigh In On Longeveron

Several institutional investors have recently modified their holdings of LGVN. Geode Capital Management LLC lifted its holdings in shares of Longeveron by 316.0% during the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after purchasing an additional 97,953 shares in the last quarter. Virtu Financial LLC acquired a new stake in Longeveron in the 4th quarter valued at approximately $53,000. Jane Street Group LLC acquired a new stake in Longeveron in the 4th quarter valued at approximately $35,000. Northern Trust Corp acquired a new stake in Longeveron in the 4th quarter valued at approximately $31,000. Finally, State Street Corp acquired a new stake in Longeveron in the 3rd quarter valued at approximately $29,000. Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.